Abstract
Hypertension is still the number one global killer. No matter what causes are, lowering blood pressure can significantly reduce cardiovascular complications, cardiovascular death, and total death. Unfortunately, some hypertensive individuals simply do not know having hypertension. Some knew it but either not being treated or treated but blood pressure does not achieve goal. The reasons for inadequate control of blood pressure are many. One important reason is that we are not very familiar with antihypertensive agents and less attention has been paid to comorbidities, complications as well as the hypertension-modified target organ damage in patients with hypertension. The right antihypertensive drug was not given to the right hypertensive patients at right time. This reviewer studied comprehensively the literature, hopefully that the review will help improve antihypertensive drug selection and antihypertensive therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ABPM:
-
Ambulatory blood pressure monitoring
- ACC:
-
American College of Cardiology
- ACE:
-
Angiotensin-converting enzyme
- AHA:
-
American Heart Association
- ARB:
-
Angiotensin II receptor blocker ARB
- ASCVD:
-
Atherosclerotic cardiovascular disease
- BP:
-
Blood pressure
- BSA:
-
Body surface area
- CCB:
-
Calcium channel blocker
- CK-MB:
-
Creatine kinase-MB
- DHP:
-
Dihydropyridine
- ECG:
-
Electrocardiogram
- eGFR:
-
Estimated Glomerular Filtration Rate
- ENaC:
-
Epithelial sodium channel
- ESC:
-
European Society of Cardiology
- ESH:
-
European Society of Hypertension
- ESKD:
-
End-stage kidney disease
- HBPM:
-
Home blood pressure monitoring
- HELLP:
-
Hemolysis, elevated liver enzymes, and low platelets
- HFpEF:
-
Ejection fraction preserved heart failure
- HMOD:
-
Hypertension-modified organ damage
- MAP:
-
Mean arterial pressure
- NEDD4L:
-
Neural precursor cell expressed, developmentally down-regulated 4, like E3 ubiquitin Protein ligase
- NO:
-
Nitric oxide
- NSAIDs:
-
Non-steroidal anti-inflammatory drugs
- NT-proBNP:
-
N-terminal prohormone of brain natriuretic peptide
- MRI:
-
Magnetic resonance imaging
- PWV:
-
Pulse wave velocity
- RAAS:
-
Renin–angiotensin–aldosterone system
- TIA:
-
Transient ischemic attack
- VSMC:
-
Vascular smooth muscle cells
References
A global brief on Hypertension, Silent killer, global public health crisis, World Health Day 2013. www.who.int. Printed by WHO Document number: WHO/DCO/WHD/2013.2. Any queries regarding this document should be addressed to: communications@who.int
ABC-H Investigators, Roush GC, Fagard RH, Salles GF, Pierdomenico SD, Reboldi G, Verdecchia P, Eguchi K, Kario K, Hoshide S, Polonia J, de la Sierra A, Hermida RC, Dolan E, Zamalloa H (2014) Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13,844 patients with hypertension. J Hypertens 32:2332–2340. https://doi.org/10.1097/hjh.0000000000000355
ACOG (The American College of Obstetricians and Gynecologists) (2018) Committee opinion: optimizing postpatum care. Obstetrics and Gyneology 131(5):e140–e150
ACOG Committee Opinion No. 767 Summary: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period. Obstet Gynecol 133(2):409–412. https://doi.org/10.1097/aog.0000000000003082
ADA: Standards of Medical Care in Diabetes. Diabetes Care (2016) 39(Suppl. 1): S1–S2 https://doi.org/10.2337/dc16-s001
AIRE Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 342 (8875):821–828
Abela R, Ivanova S, Lidder S, Morris R, Hamilton G (2009) An analysis comparing open surgical and endovascular treatment of atherosclerotic renal artery stenosis. Eur J Vasc Endovasc Surg 38:666–675
Acelajado MC, Hughes ZH, Oparil S, Calhoun DA (2019a) Treatment of resistant and refractory hypertension. Circ Res 124(7):1061–1070. https://doi.org/10.1161/circresaha.118.312156 PMID: 30920924
Acelajado MC, Hughes ZH, Oparil S, Calhoun DA (2019) Treatment of resistant and refractory hypertension. Circulat Res 124:1061–1070. Originally Published 28 Mar 2019. https://doi.org/10.1161/CIRCRESAHA.118.312156
Agabiti Rosei E, Rizzoni D (2007) Metabolic profile of Nebivolol, a beta-adrenoceptor antagonist, with unique characteristics. Drugs 67(8): 1097–107. https://doi.org/10.2165/00003495-200767080-00001. pmid 17521213
Agarwal R (1999) Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int 55:1528–1535
Agarwal R, Alborzi P, Satyan S, Light RP (2009) Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 53:500–507 [PubMed: 19153263]
Agarwal R, Lewis R, Davis JL, Becker B (2001) Lisinopril therapy for hemodialysis hypertension: Hemodynamic and endocrine responses. Am J Kidney Dis 38:1245–1250 [PubMed: 11728957]
Agarwal R, Nissenson AR, Battle D, Coyne DW, Trout JR, Warnock DG (2003) Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 115:291–297
Agarwal R, Sinha AD (2009) Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension 53:860–866 [PubMed: 19273737]
Agarwal R, Sinha AD (2012) Thiazide diuretics in advanced chronic kidney disease. J Am Soc Hypertens 6(5):299–308 [PubMed: 22951101]
Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG (2014) Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant 29:672–681
Agostoni A, Cicardi M, Cugno M, Zingale LC, Gioffre D, Nussberger J (1999) Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology 44:21–25
Ahmed ME, Walker JM, Beevers DG, Beevers M (1986) Lack of difference between malignant and accelerated hypertension. Br Med J (Clin Res Ed) 292(6515):235–237
Al Khaja KA, Sequeira RP, Alkhaja AK, Damanhori AH (2016) Antihypertensive drugs and male sexual dysfunction: a review of adult hypertension guideline recommendations. J Cardiovasc Pharmacol Ther. 21(3):233–244. https://doi.org/10.1177/1074248415598321
Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR (2012) Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 59:926–933
Amar J, Vernier I, Rossignol E, Bongard V, Arnaud C, Conte JJ, Salvador M, Chamontin B (2000) Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int 57:2485–2491 [PubMed: 10844617]
Ambale-Venkatesh B, Yang X, Wu CO, Liu K, Hundley WG, McClelland R, Gomes AS, Folsom AR, Shea S, Guallar E, Bluemke DA, Lima JAC (2017) Cardiovascular event prediction by machine learning: the multi-ethnic study of atherosclerosis. Circ Res 121(9):1092–1101. https://doi.org/10.1161/circresaha.117.311312 Epub 2017 Aug 9
American Academy of Pediatrics Committee on Drugs (2001a) Transfer of drugs and other chemicals into human milk. Pediatrics 108(3):776–789
American Academy of Pediatrics Committee on Drugs (2001b) Transfer of drugs and other chemicals into human milk. Pediatrics. 108(3):776–89. September 2001. PMID 11533352
American College of Obstetricians and Gynecologists (2013) Task Force on Hypertension in Pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 122:1122–1131
American Diabetes Associations (2013) Standards of medical care in diabetes—2013. Diabetes Care 36(suppl 1):S11–S66 [PubMed: 23264422]
Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C et al (2013a) INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 368:2355–2365
Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, Heritier S, Li Q, Woodward M, Simes RJ, Davis SM, Chalmers J (2013b) Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage. N Engl J Med 368(25):2355–2365. https://doi.org/10.1056/nejmoa121460
Angulo J, Wright HM, Cuevas P, González-Corrochano R, Fernández A, Cuevas B, La Fuente JM, Gupta S, Sáenz de Tejada I. Nebivolol dilates human penile arteries and reverses erectile dysfunction in diabetic rats through enhancement of nitric oxide signaling. J Sex Med. 2010 Aug;7(8):2681–97. https://doi.org/10.1111/j.1743-6109.2010.01710.x
Aram V. Chobanian, George L. Bakris, Henry R. Black, William C. Cushman, Lee A. Green, Joseph L. Izzo, Daniel W. Jones, Barry J. Materson, Suzanne Oparil, Jackson T. Wright, Edward J. Roccella, and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003, 289(19):2560–72. DOI: https://doi.org/10.1001/jama.289.19.2560
Arjun D. Sinha and Rajiv Agarwal. Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD. CJASN May 2019, 14 (5) 757–764. https://doi.org/10.2215/CJN.04330418
Armanini D, Andrisani A, Bordin L, Sabbadin C (2016) Spironolactone in the treatment of polycystic ovary syndrome. Expert Opin Pharmacother 17(13):1713–1715. https://doi.org/10.1080/14656566.2016.1215430 pmid 27450358
Armanini D, Castello R, Scaroni C, Bonanni G, Faccini G, Pellati D, Bertoldo A, Fiore C, Moghetti P (2007) Treatment of polycystic ovary syndrome with spironolactone plus licorice. Eur J Obstet Gynecol Reprod Biol 131(1):61–67. https://doi.org/10.1016/j.ejogrb.2006.10.013 pmid 17113210
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED (2019) ACC/AHA Guideline on the primary prevention of cardiovascular disease. J Am College Cardiol. https://doi.org/10.1016/j.jacc.2019.03.010
Arnold WC (1984) Efficacy of metolazone and furosemide in children with furosemide-resistant edema. Pediatrics 74(5):872–875
Asare K (2009) Management of loop diuretic resistance in the intensive care unit. Am J Health Syst Pharm 66(18):1635–1640. https://doi.org/10.2146/ajhp090068
Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007 May 26;369(9575):1791–1798. https://doi.org/10.1016/s0140-6736(07)60712-0. Review. PMID:17512048
Bakris G (May 2009). An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. J. Cardiovasc. Pharmacol. 53 (5): 379–87. https://doi.org/10.1097/fjc.0b013e31819fd501. pmid 19454898
Bakris G (May 2009). An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. J. Cardiovasc. Pharmacol. 53 (5): 379–87. https://doi.org/10.1097/fjc.0b013e31819fd501. pmid 19454898
Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000; 36(3):646–661. [PubMed: 10977801]
Baldwin CM, Keam SJ (2009) Nebivolol In the Treatment of Hypertension in the US. Am J Cardiovasc Drugs 9(4):253–260
Bangalore S, Kumar S, Wetterslev J, Messerli FH (2011) Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 342:d2234
Bangalore S, Parkar S, Grossman E, Messerli FH (2007) A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 100(8):1254–1262
Bangash F, Agarwal R (2009) Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 4(3):656–664 [PubMed: 19261815]
Barzilay JI, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Black HR, Cushman WC, Ford CE, Margolis KL, Moloo J, Oparil S, Piller LB, Simmons DL, Sweeney ME, Whelton PK, Wong ND, Wright JT Jr (2012) ALLHAT Collaborative Research Group Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes 5:153–162
Barzilay JI, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Black HR, Cushman WC, Ford CE, Margolis KL, Moloo J, Oparil S, Piller LB, Simmons DL, Sweeney ME, Whelton PK, Wong ND, Wright JT Jr; ALLHAT Collaborative Research Group. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes. 2012 Mar 1;5(2):153–62. https://doi.org/10.1161/circoutcomes.111.962522
Bath PMW, Woodhouse L, Scutt P, Krishnan K, Wardlaw JM, Bereczki D, Sprigg N, Berge E, Beridze M, Caso V, Chen C, Christensen H, Collins R, El Etribi A, Laska AC, Lees KR, Ozturk S, Phillips S, Pocock S, de Silva HA, Szatmari S, Utton S, Thomas D, Venables G, Amarenco P, Muir K, Shone A, Skene A, Whynes D, Beridze M, Bladin C, Caso V, Chen C, Chang HM, Czlonkowska A, Díez-Tejedor E, Ghani AR, Gommans J, Navarro J, Ntaios G, Prasad K, Wong L, Wang YJ, Sandercock PAG, Asplund K, Baigent C, Weaver C, Foster H, Ankolekar S, England T, Rashid P, Sare G, Willmot M, Ellender S, Grant S, MacAlpine S, Adrian M, Durham A, Ferentzi U, Payne T, Cobane L, Kaur L, Keeling J, Stevens V, Whittamore K, Whysall B, Hazle D, Jones T, Randall C, Sampson M, Clarke W, Dunn L, Smallwood Y, Adami A, Becker J, Cala L, Casado A, Dineen R, Koumellis P, Gray L, Houlton A, Leonardi-Bee J, Renton C, Tracy M, Woodhouse L, Haywood L, Walker E, Watson G, Yeung S, Baldwin RN, Mead G, Chen CPLH, Wijekoon CN.ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. Lancet. 2015 Feb 14;385(9968):617–628. https://doi.org/10.1016/s0140-6736(14)61121-1. Epub 2014 Oct 21
Bath PMW, Woodhouse L, Scutt P, Krishnan K, Wardlaw JM, Bereczki D, Sprigg N, Berge E, Beridze M, Caso V, Chen C, Christensen H, Collins R, El Etribi A, Laska AC, Lees KR, Ozturk S, Phillips S, Pocock S, de Silva HA, Szatmari S, Utton S, Thomas D, Venables G, Amarenco P, Muir K, Shone A, Skene A, Whynes D, Beridze M, Bladin C, Caso V, Chen C, Chang HM, Czlonkowska A, Díez-Tejedor E, Ghani AR, Gommans J, Navarro J, Ntaios G, Prasad K, Wong L, Wang YJ, Sandercock PAG, Asplund K, Baigent C, Weaver C, Foster H, Ankolekar S, England T, Rashid P, Sare G, Willmot M, Ellender S, Grant S, MacAlpine S, Adrian M, Durham A, Ferentzi U, Payne T, Cobane L, Kaur L, Keeling J, Stevens V, Whittamore K, Whysall B, Hazle D, Jones T, Randall C, Sampson M, Clarke W, Dunn L, Smallwood Y, Adami A, Becker J, Cala L, Casado A, Dineen R, Koumellis P, Gray L, Houlton A, Leonardi-Bee J, Renton C, Tracy M, Woodhouse L, Haywood L, Walker E, Watson G, Yeung S, Baldwin RN, Mead G, Chen CPLH, Wijekoon CN.ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomized controlled trial. Lancet. 2015 Feb 14;385(9968):617–628. https://doi.org/10.1016/s0140-6736(14)61121-1
Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ (2008) HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887–1998
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P (2017) American Heart Association Statistics Committee and Stroke Statistics Subcommittee for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 135(10):e146–e603
Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van Horn L, Tracy RP, Lloyd-Jones DM (2012) Lifetime risks of cardiovascular disease. N Engl J Med 366(4):321–329. https://doi.org/10.1056/nejmoa1012848
Bertram Pitt, M.D., Faiez Zannad, M.D., Willem J. Remme, M.D., Robert Cody, M.D., Alain Castaigne, M.D., Alfonso Perez, M.D., Jolie Palensky, M.S., and Janet Wittes, Ph.D. for the Randomized Aldactone Evaluation Study Investigators* The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. N Engl J Med 1999; 341:709–717 https://doi.org/10.1056/nejm199909023411001
Binkley PF, Haas GJ, Starling RC, Nunziata E, Hatton PA, Leier CV, Cody RJ (1993) Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J Am Coll Cardiol 21(3):655–661. https://doi.org/10.1016/0735-1097(93)90098-l
van Blijderveen JC, Straus SM, Rodenburg EM, Zietse R, Stricker BH, Sturkenboom MC, Verhamme KM (2014) Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide. Am J Med 127:763–771
Bobrie G, Frank M, Azizi M (2012) Sequential nephron blockade versus sequential renin–angiotensin system blockade in resistant hypertension. J Hypertens 30:1656–1664
Booth JN 3rd, Colantonio LD, Gottesman RF, Howard G, Lackland DT, O’Brien EC, Oparil S, Ravenell J, Safford MM, Seals SR, Shimbo D2, Shea S, Spruill TM, Tanner RM2, Muntner P (2017) Incident cardiovascular disease among adults with blood pressure < 140/90 mm Hg. Circulation 136(9):798–812. https://doi.org/10.1161/circulationaha.117.027362. Epub 2017 Jun 20
Bousquet P, Feldman J, Tibirica E, Bricca G, Greney H, Dontenwill M, Stutzmann J, Belcourt A (1992) Imidazoline receptors: a new concept in central regulation of the arterial blood pressure. Am J Hypertens. 1992 Apr;5(4 Pt 2):47S–50S
Bowman BN, Nawarskas JJ, Anderson JR (2016) Treating diuretic resistance: an overview. Cardiol Rev 24(5):256–260. https://doi.org/10.1097/crd.0000000000000116
Bozzo P, Einarson A (2009) Use of diuretics during pregnancy. Can Fam Physician. 55(1):44–45. PMCID: PMC2628835. PMID: 19155365
Bragg-Gresham JL, Fissell RB, Mason NA, Bailie GR, Gillespie BW, Wizemann V, Cruz JM, Akiba T, Kurokawa K, Ramirez S, Young EW (2007) Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis 49(3):426–431
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S (2001) RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869
Brisco-Bacik MA, Ter Maaten JM, Houser SR, Vedage NA, Rao V, Ahmad T, Wilson FP, Testani JM (2018) Outcomes Associated With a Strategy of Adjuvant Metolazone or High-Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis. J Am Heart Assoc. 7(18):e009149
Brown NJ (2003) Eplerenone: Cardiovascular Protection. Circulation 107(19):2512–2518
Brown NJ, Snowden M, Griffin MR (1997) Recurrent angiotensin-converting enzyme inhibitor– associated angioedema. JAMA 278:232–233
Brown MJ, Williams B, Morant S, et al; for the PATHWAY Studies Group. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol 2015; published online Oct 19. http://dx.doi. org/https://doi.org/10.1016/s2213-8587(15)00377-0
Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes G, Sever P, Salsbury J, Mackenzie IS, Padmanabhan S, MacDonald TM. British Hypertension Society’s Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol 2016; 4:136–147
Brunstrom M, Carlberg B (2018) Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med 178:28–36
Brunström M, Carlberg B (2018) Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med. 178(1):28–36
Brunton, Laurence; Lazo, John S.; Parker, Keith L., eds. (2006). Goodman & Gilman’s The Pharmacological Basis of Therapeutics (11th ed.). New York: McGraw-Hill. pp. 749–753
Bundkirchen A, Brixius K, Bölck B, Nguyen Q, Schwinger RH (January 2003). Beta 1-adrenoceptor selectivity of Nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies. Eur. J. Pharmacol. 460 (1): 19–26. https://doi.org/10.1016/s0014-2999(02)02875-3. pmid 12535855
Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, He H, Chen J, Whelton PK, He J (2017) Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis. JAMA Cardiol. 2(7):775–781. https://doi.org/10.1001/jamacardio.2017.1421
Butalia S, Audibert F, Côté AM, Firoz T, Logan AG, Magee LA, Mundle W, Rey E, Rabi DM, Daskalopoulou SS, Nerenberg KA (2018) Hypertension Canada. Hypertension Canada’s 2018 Guidelines for the Management of Hypertension in Pregnancy. Can J Cardiol 34(5):526–531. https://doi.org/10.1016/j.cjca.2018.02.021. PMID: 29731014
Cai G, Zheng Y, Sun X, Chen X (2013) Prevalence, awareness, treatment, and control of hypertension in elderly adults with chronic kidney disease: results from the survey of Prevalence, Awareness, and Treatment Rates in Chronic Kidney Disease Patients With Hypertension in China. J Am Geriatr Soc 61(12):2160–2167 [PubMed: 24479145]
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K (2008) A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Carey. Resistant Hypertension: Diagnosis, Evaluation, and Treatment. Circulation 117: e510–e526. Originally Published 24 Jun 2008. https://doi.org/10.1161/CIRCULATIONAHA.108.189141
Carter BL, Einhorn PT, Brands M, He J, Cutler JA, Whelton PK, Bakris GL, Brancati FL, Cushman WC, Oparil S, Wright JT Jr; Working Group from the National Heart, Lung, and Blood Institute. Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension. 2008 Jul;52(1):30–6. https://doi.org/10.1161/hypertensionaha.108.114389. Epub 2008 May 26
Carty DM, Delles C, Dominiczak AF (2010) pre-eclampsia and future maternal health. J Hypertens 28(7):1349–1355
de Carvalho JG, Dunn FG, Lohmöller G, Frohlich ED (1977) Hemodynamic correlates of prolonged thiazide therapy: comparison of responders and nonresponders. Clin Pharmacol Ther 22:875–880
Catala-Lopez F, Macias Saint-Gerons D, Gonzalez-Bermejo D, Rosano GM, Davis BR, Ridao M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos R, Hutton B.Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses. PLoS Med 2016;13: e1001971. https://doi.org/10.1371/journal.pmed.1001971. eCollection 2016 Mar
Caughey AB (2017) Apgar scores: two methodologic studies exploring their use in research. Paediatr Perinat Epidemiol 31(4):346–347. https://doi.org/10.1111/ppe.12379 Epub 2017 Jul 3
Chen CW, Jaffe IZ, Karumanchi SA (2014) Pre-eclampsia and cardiovascular disease. Cardiovasc Res 101(4):579–586
Chen X, Zhai Z, Huang K, Xie W, Wan J, Wang C. Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a systemic review and meta-analysis. Clin Respir J. 2018. Jun;12(6):2065–2074. https://doi.org/10.1111/crj.12774
Chen N, Zhou M, Yang M, Guo J, Zhu C, Yang J, Wang Y, Yang X, He L (2010). Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Systematic Rev 8(8): CD003654. https://doi.org/10.1002/14651858.cd003654.pub4. pmid 20687074
Chrysant SG (2018) Aggressive systolic blood pressure control in older subjects: benefits and risks. Postgrad Med 130(2):159–165. https://doi.org/10.1080/00325481.2018.1433434
Cobos-Puc L, Aguayo-Morales H (2019) cardiovascular effects mediated by imidazoline drugs: an update. Cardiovasc Hematol Disord: Drug Targets 19(2):95–108. https://doi.org/10.2174/1871529x18666180629170336
Committee on Obstetric Practice. Committee Opinion No. 623: Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. Obstet Gynecol. 2015;125: 521–5
Conn, Jennifer J.; Jacobs, Howard S. (1998). Managing hirsutism in gynaecological practice. BJOG: An International Journal of Obstetrics and Gynaecology. 105 (7): 687–696. https://doi.org/10.1111/j.1471-0528.1998.tb10197.x issn 1470-0328
Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG (1992) Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327:1912–1918
Costas T (2016) Roland Schmieder; Giuseppe Mancia. Interventional Therapies for Secondary and Essential Hypertension. Springer. p. 44. ISBN 978–3-319-34141-5
Cruickshank JM (2017) The Role of Beta-Blockers in the Treatment of Hypertension. Adv Exp Med Biol 956:149–166. https://doi.org/10.1007/5584_2016_36
Culleton BF, Larson MG, Kannel WB, Levy D (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131(1):7–13
Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, Russell RP (2015) The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies. Am J Hypertens 28:1376–1385. https://doi.org/10.1093/ajh/hpv031
Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, Ezzati M (2009) The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 6:e1000058. https://doi.org/10.1371/journal.pmed.1000058
David S.H Bell. Advantages of a third-generation β-blocker in patients with diabetes mellitus. The American Journal of Cardiology 2004, 93 (9, Supplement 1): 49–52
David A. Warrell; Edward J. Benz; Timothy M. Cox; John D. Firth (2003). Oxford Textbook of Medicine. Oxford University Press. pp. 1–. ISBN 978–0-19-262922-7
Davis B, Cutler JA, Gordon D. Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA: J Am Med Assoc. 2002;288(23):2981–97. https://doi.org/10.1001/jama.288.23.2981. pmid 12479763
Delyani John A (2000) Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology. Kidney Int 57(4):1408–1411
Devlin JW, Seta ML, Kanji S, Somerville AL (2004) Fenoldopam versus nitroprusside for the treatment of hypertensive emergency. Ann Pharmacother 38(5):755–759
Donald W. Seldin; Gerhard H. Giebisch (23 September 1997). Diuretic Agents: Clinical Physiology and Pharmacology. Academic Press. pp. 630–632. ISBN 978–0-08-053046-8. Archived from the original on 4 July 2014
Donna K. Arnett, Roger S. Blumenthal, Michelle A. Albert, Andrew B. Buroker, Zachary D. Goldberger, Ellen J. Hahn, Cheryl Dennison Himmelfarb, Amit Khera, Donald Lloyd-Jones, J. William McEvoy, Erin D. Michos, Michael D. Miedema, Daniel Muñoz, Sidney C. Smith Jr., Salim S. Virani, Kim A. Williams Sr., Joseph Yeboah and Boback Ziaeian. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. Volume 74, Issue 10, September 2019. DOI: https://doi.org/10.1016/j.jacc.2019.03.010
Douglas KA, Redman CW (1994) Eclampsia in the United Kingdom. BMJ 309:1395–1400
Duarte, JD; Cooper-Dehoff, RM (2010). ”Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics”. Expert Review of Cardiovascular Therapy. 8 (6): 793–802. https://doi.org/10.1586/erc.10.27. pmc 2904515 pmid 20528637. nihmsid: NIHMS215063
Duley L (2009) The global impact of pre-eclampsia and eclampsia. Semin Perinatol 33(3):130–137
Durros G, Jaff M, Mathiak L, Dorros G, He T (2002) Multicenter Registry Participants. Multicenter Palmaz stent renal artery stenosis revascularization registry report: four-year follow–up of 1068 successful patients. Catheter Cardiovasc Interv 55:182–188
Dworkin LD, Cooper CJ (2009) Renal-artery stenosis. N Engl J Med 361:1972–1978
Düsing R (2005) Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs 65(6):773–786
Eckman A, Dobs A (November 2008). Drug-induced gynecomastia. Expert Opin Drug Saf. 7 (6): 691–702. https://doi.org/10.1517/14740330802442382. pmid 18983216
Egan BM, Zhao Y, Axon RN (2010) US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 303(20):2043–2050 [PubMed: 20501926]
Ehud Grossman. Blood Pressure: The Lower, the Better. The con side Diabetes Care. 2011 May; 34(Suppl 2): S308–S312. Published online 2011 Apr 22. doi: https://doi.org/10.2337/dc11-s245. PMCID: PMC3632198. PMID: 21525474
Eirin A, Textor SC, Lerman LO (2019) Novel therapeutic strategies for renovascular disease. Curr Opin Nephrol Hypertens 28(4):383–389. https://doi.org/10.1097/mnh.0000000000000513
Elisabeta Badila, Emma Tintea. How to manage renovascular hypertension. An article from the e-journal of the ESC Council for Cardiology Practice. Vol. 13, N8 – 09 Dec 2014
Ernst ME1, Moser M. Use of diuretics in patients with hypertension. N Engl J Med. 2009 Nov 26;361(22):2153–64. https://doi.org/10.1056/nejmra0907219
F J Mackay, G L Pearce, and R D Mann. Cough and angiotensin II receptor antagonists: cause or confounding? Br J Clin Pharmacol. 1999 Jan; 47(1): 111–114. doi: https://doi.org/10.1046/j.1365-2125.1999.00855.x PMCID: PMC2014204. PMID: 10073748
Fellner RC, Cook AK, O’Connor PM, Zhang S, Pollock DM, Inscho EW (2014) High-salt diet blunts renal autoregulation by a reactive oxygen species-dependent mechanism. Am J Physiol Renal Physiol 307(1):F33–F40 [PubMed: 24872316]
Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE (1996) Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 49:1379–1385 [PubMed: 8731103]
Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche T, Durkan A, Hissaria P, Blombery P, Barbour TD (2018) Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Intern Med J. 48(6):624–636. https://doi.org/10.1111/imj.13804
Freis ED (1989) Critique of the clinical importance of diurectic-induced hypokalemia and elevated cholesterol level. Arch Intern Med 149(12):2640–2648
Fujimura N, Noma K, Hata T, Soga J, Hidaka T, Idei N, Fujii Y, Mikami S, Maruhashi T, Iwamoto Y, Kihara Y, Chayama K, Kato H, Liao JK, Higashi Y; ROCK Study Group. Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. Clin Pharmacol Ther. 2012; 91:289–297. https://doi.org/10.1038/clpt.2011.227
GBD 2016 Alcohol Collaborators. Collaborators (514). Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018 Sep 22; 392(10152):1015-1035. https://doi.org/10.1016/s0140-6736(18)31310-2. Epub 2018 Aug 23
Galougahi, Keyvan (February 19, 2016). β3 Adrenergic Stimulation Restores Nitric Oxide/Redox Balance and Enhances Endothelial Function in Hyperglycemia. JAHA. 5 (2): e002824 https://doi.org/10.1161/jaha.115.002824. pmc 4802476. pmid 26896479
Garovic V, Textor S (2005) Renovascular Hypertension and Ischemic Nephropathy. Circulation 112:1362–1374
Garthwaite E, Bhandari S (2009) The effects of angiotensin converting enzyme inhibitors on potassium homeostasis in dialysis patients with and without residual renal function. Artif Organs 33:641–647
Georgianos PI, Agarwal R (2016) Pharmacotherapy of hypertension in chronic dialysis patients. Clin J Am Soc Nephrol 11:2062–2075
Georgianou E, Georgianos PI, Petidis K, Athyros VG, Sarafidis PA, Karagiannis A (2018) Antihypertensive therapy in acute ischemic stroke: where do we stand? J Hum Hypertens 32(12):799–807. https://doi.org/10.1038/s41371-018-0105-7 Epub 2018 Sep 19
Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 202. Obstet Gynecol. 2019;133: e1–25; Chronic hypertension in pregnancy. ACOG Practice Bulletin No. 203. Obstet Gynecol. 2019; 133: e26-50
Gielen W, Cleophas TJ, Agrawal R (August 2006). Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 44 (8): 344–57. https://doi.org/10.5414/cpp44344. pmid 16961165
Giorgio Olivetti, Elena Cigola, Roberta Maestri, Costanza Lagrasta, Demenico Corradi. Recent advances in cardiac hypertrophy. Cardiovas Res, 45 (1):68–75, https://doi.org/10.1016/S0008-6363(99)00298-9
Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES). AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME–PART 1. Endocr Pract. 2015 Nov;21(11):1291–300. https://doi.org/10.4158/ep15748.dsc
Gornik HL, Persu A, Adlam D, Aparicio LS, Azizi M6, Boulanger M, Bruno RM, de Leeuw P, Fendrikova-Mahlay N, Froehlich J, Ganesh SK, Gray BH, Jamison C, Januszewicz A, Jeunemaitre X, Kadian-Dodov D, Kim ES, Kovacic JC, Mace P, Morganti A, Sharma A, Southerland AM, Touzé E9 van der Niepen P, Wang J, Weinberg I, Wilson S, Olin JW, Plouin PF. First International Consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med. 2019 Apr;24(2):164–189. https://doi.org/10.1177/1358863x18821816. Epub 2019 Jan 16
Grams ME, Surapaneni A, Ballew SH, Appel LJ, Boerwinkle E, Boulware LE, Chen TK, Coresh J, Cushman M, Divers J, Gutiérrez OM (2019) APOL1 kidney risk variants and cardiovascular disease: an individual participant data meta-analysis. J Am Soc Nephrol. pii: ASN.2019030240. https://doi.org/10.1681/asn.2019030240
Gray BH, Olin JW, Childs MB, Sullivan TM, Bacharach JM (2002) Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure. Vasc Med. 7:275–279
Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342:905–912, pmid:10738048
Grosskopf I, Rabinovitz M, Rosenfeld JB (1986) Combination of furosemide and metolazone in the treatment of severe congestive heart failure. Isr J Med Sci 22(11):787–790
Grossman E, Messerli FH, Neutel JM (2000) Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors? Arch Intern Med 160:1905–1911
Guanmin Chen, Finlay A McAlister, Robin Walker, Brenda R Hemmelgarn, Norm R C Campbell. Cardiovascular Outcomes in Framingham Participants With Diabetes The Importance of Blood Pressure. Hypertension 2011, 57(5):891–7, DOI: https://doi.org/10.1161/hypertensionaha.1https://doi.org/10.162446
Han, Da Hee (29 August 2017). Spironolactone and Amiloride Effective in Drug-Resistant Hypertension. MPR. Haymarket Media, Inc. Retrieved 9 June 2018
Hans-Jörg Helmlin, André Mürner, Samuel Steiner, Christina Weber, Hans Geyer, Sven Guddat, Deutsche Sporthochschule Köln, Wilhelm Schänzer, Mario Thevis. Detection of the diuretic hydrochlorothiazide in a doping control urine sample as the result of a non-steroidal anti-inflammatory drug (NSAID) tablet contamination. August 2016, Forensic science international 267, DOI: https://doi.org/10.1016/j.forsciint.2016.08.029
Hansson L, Svensson A, Gudbrandsson T, Sivertsson R (1983) Treatment of hypertension with beta-blockers with and without intrinsic sympathomimeticactivity. J Cardiovasc Pharmacol 5(Suppl 1):S26–S29
Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D, Beyene J, Shah PS (2012) The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalemia and acute kidney injury: systematic review and meta-analysis. BMJ 344: e42
Haruhara K, Tsuboi N, Koike K et al (2014) Renal histopathological findings in relation to ambulatory blood pressure in chronic kidney disease patients. Hypertens Res [e-pub ahead of print], 2014 Sep 18. http://dx.doi.org/10.1038/hr.2014.140
Hayashi SY, Seeberger A, Lind B, Gunnes S, Alvestrand A, do Nascimento MM, Lindholm B, Brodin LA (2008) Acute effects of low and high intravenous doses of furosemide on myocardial function in anuric haemodialysis patients: a tissue Doppler study. Nephrol Dial Transplant 23:1355–1361
Head G, Burke SL (2000) I1 imidazoline receptors in cardiovascular regulation: the place of rilmenidine. Am J Hypertens (6 Pt 2):89S–98S
Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, Gallagher M, Roberts MA, Cass A, Neal B, Perkovic V (2009) Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 373:1009–1015 [PubMed: 19249092]
Henry R. Black, William J. Elliot. A Companion to Braunwald’s Heart Disease. Second Edition. Elsevier Saunders, 2013; Ch 8, pg. 69–79
Heran BS, Chen JM, Wang JJ, Wright JM. Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension. Cochrane Database Syst Rev. 2012 Nov 14;11:CD008167. https://doi.org/10.1002/14651858.cd008167.pub3
Hermida RC, Ayala DE, Mojon A, Fernandez JR (2011) Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 22(12):2313–2321 [PubMed: 22025630]
Hermida RC, Ayala DE, Mojón A, Chayán L, Domínguez MJ, Fontao MJ, Soler R, Alonso I, Fernandez JR (2008) Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension. Chronobiol Int 25:950–970
Hermida RC, Smolensky MH, Ayala DE et al (2014) Abnormalities in chronic kidney disease of ambulatory blood pressure 24 h patterning and normalization by bedtime hypertension chronotherapy. Nephrol Dial Transplant 29(6):1160–1167 [PubMed: 24009285]
Hermida RC, Ayala DE, Mojón A, Chayán L, Domínguez MJ, Fontao MJ, Soler R, Alonso I, Fernandez JR. Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension. Chronobiol Int. 2008; 25:950–970.https://doi.org/10.1080/07420520802544589
Herrmann, S., & Textor, S. C. (2018). Current Concepts in the Treatment of Renovascular Hypertension. American Journal of Hypertension, 2018, 31(2), 139–149. https://doi.org/10.1093/ajh/hpx154
Hirschl MM, Binder M, Bur A, Herkner H, Müllner M, Woisetschläger C, Laggner AN (1997) Safety and efficacy of urapidil and sodium nitroprusside in the treatment of hypertensive emergencies. Intensive Care Med 23(8):885–888
Hockerman GH, Peterson BZ, Johnson BD, Catterall WA (1997) Molecular Determinants of Drug Binding and Action on L-Type Calcium Channels. Annu Rev Pharmacol Toxicol 37:361–396
Holsboer F (1999) The Rationale for Corticotropin-Releasing Hormone Receptor (CRH-R) Antagonists to Treat Depression and Anxiety. J. Psychiatratr. Res. 33:181–214
Hon-Yen Wu, Huang Jenq-Wen, Lin Hung-Ju, Liao Wei-Chih, Peng Yu-Sen, Hung Kuan-Yu, Kwan-Dun Wu, Yu-Kang Tu, Chien Kuo-Liong (2013) Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ 347:f6008. https://doi.org/10.1136/bmj.f6008
Huang Y, Wang S, Cai X, Mai W, Hu Y, Tang H, Xu D (2013) Prehypertension and incidence of cardiovascular disease: a meta-analysis. BMC Med 2(11):177. https://doi.org/10.1186/1741-7015-11-177
Huang Y1, Cai X, Li Y, Su L, Mai W, Wang S, Hu Y, Wu Y, Xu D. Prehypertension and the risk of stroke: a meta-analysis. Neurology. 2014 Apr 1;82(13):1153–61. https://doi.org/10.1212/wnl.0000000000000268
Inrig JK, Patel UD, Gillespie BS, Hasselblad V, Himmelfarb J, Reddan D, Lindsay RM, Winchester JF, Stivelman J, Toto R, Szczech LA (2007) Relationship between interdialytic weight gain and blood pressure among prevalent hemodialysis patients. Am J Kidney Dis 50:108–118 [PubMed: 17591530]
Israili ZH, Hall WD (1992) Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 117:234–242
Jaillon P (1990) Relevance of intrinsic sympathomimetic activity for beta blockers. Am J Cardiol 66(9):21C–23C
Jaillon P. Relevance of intrinsic sympathomimetic activity for beta blockers. Am J Cardiol. 1990 Sep 25;66(9):21C-23C. PMID:1977302, https://doi.org/10.1016/0002-9149(90)90758-s
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC, Svetkey LP, Taler SJ, Townsend RR, Wright JT, Narva AS, Ortiz E (2013) 2014 evidence-based guideline for the management of high blood pressure in adults. JAMA 1097:1–14. https://doi.org/10.1001/jama.2013.284427
James D. Neaton, PhD; Richard H. Grimm Jr, MD, PhD; Ronald J. Prineas, MB, PhD; et alJeremiah Stamler, MD; Greg A. Grandits, MS; Patricia J. Elmer, PhD; Jeffrey A. Cutler, MD; John M. Flack, MD; James A. Schoenberger, MD; Robert McDonald, MD; Cora Elizabeth Lewis, MD, MSPH; Philip R. Liebson, MD; Janet Raines, MS, RD; Isabelle Joffrion, RN, MAE; Ralph E. Allen, PAC; Linda Jones, CRNP, MN; Deborah Parker; Jacqueline K. De Worth, MS, RD; Evelyn Anzelone; Doris Gunn; Ann George; JoAnn Montgomery; Gilberto S. Neri, MD; Eleanor Betz, RD; Barbara Mascitti, RD; Ellen Plank, RNNP; Brenda Peterson, RN; Tracy Remijas, MPH; Walter Washington; Irene Turner, MT; Laura Stefanie; Pamela Aye, MS, RD; Susan Madnek-Oxman, MS, RD; Helen Jones; Stephen R. Mascioli, MD, MPH; Nancy Van Heel, MS, RD; Cindy Bjerk, MS, RD; Fran Galle, RN; Patricia Laqua, RD; Margaret Miller, MT (ASCP); Liv Marit Bell, RN, MPH; Mary Ellen Robinson, MS, RD; Carolyn Thorson; Raymond Townsend, MD; Arlene Caggiula, PhD; Sinda Dianzumba, MD; Carole Ciak, RN, BSN; Marcella Link, MS, RD; Beth Hall, RD; Mary Monske, RN, BSN; Therese M. Theobald, BS, RDCS; Michelle Berry, MS, RD; Terry Coyne, MS, RD; Claire A. Bunker, PhD; Kaye Kramer, RN, BSN; Alain G. DuChene; Leslie A. Holland; Sylvia Tze, MS; Serena Sjolund; Cynthia A. Launer, MS; John Lagus, MS; Cynthia M. Miller; Kenneth H. Svendsen, MS; Arthur Leon, MD; Brian Laing, MS; Marsha McDonald, MA; Dean Surbey, MBA; Mary Kay Wiche, RD, MPH; Kimberly Kuiper; Richard Remington, PhD; Thomas J. Coates, PhD; Richard Devereux, MD; Ray W. Gifford Jr, MD; Herbert Langford, MD; Laurence McCullough, PhD; Herman A. Tyroler, MD. Treatment of Mild Hypertension Study Final Results.JAMA. 1993;270(6):713–724. https://doi.org/10.1001/jama.1993.03510060059034
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC (2014) Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 311(5):507–520. https://doi.org/10.1001/jama.2013.284427
Jennifer C (2004) Eplerenone. Proc (Bayl Univ Med Cent); Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure. Pub MedCentral.2004, 17(2): 217–20. PMC 1200656. PMID 16200104
Jeunemaitre X, Charru A, Chatellier G, Degoulet P, Julien J, Plouin PF, Corvol P, Ménard J.. Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension. Am J Cardiol1988; 62:1072–1077. pmid:3189169
Jolobe O. Malignant hypertension in lgA nephropathy. Br J Hosp Med (Lond). 2015 Mar;76(3):177. https://doi.org/10.12968/hmed.2015.76.3.177
Joseph G. Murphy, Margaret a. Lloyd (editors in chief). Associate Editors – Peter A. Brady, Lyle J. Olson, Raymond C. Shields. Mayo Clinic Cardiology. Concise Textbook, Fourth Edition. Mayo Clinic Scientific Press, Mayo Foundation for Medical Education and Research 2013; Ch 47, pg. 470–474
JosephMcGraw,MitchellCherney, KatherineBichler, ArminGerhardt, Mirielle Nauman..The Relative Role of CYP3A4 and CYP3A5 in Eplerenone Metabolism. Toxicology Letters. Available online 10 August 2019. Toxicology Letters. 2019, 315: 9–13, https://doi.org/10.1016/j.toxlet.2019.08.003
Joshua I. Barzilay, MD; Barry R. Davis, Jeffrey A. Cutler, Sara L. Pressel, Paul K. Whelton, Jan Basile, Karen L. Margolis, Stephen T. Ong, Laurie S. Sadler, John Summerson, ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166:2191–2201. pmid:17101936
Judd E, Calhoun DA (2015) Management of hypertension in CKD: beyond the guidelines. Adv Chronic Kidney Dis. 22(2):116–122. https://doi.org/10.1053/j.ackd.2014.12.001
Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351(6):543–551
K Kramkowski, Andrzej Mogielnicki, W Buczko. The physiological significance of the alternative pathways of angiotensin II production. Journal of physiology and pharmacology.2007, 57(4):529–39
Kalra PA, Guo H, Kausz AT, Gilbertson DT, Liu J, Chen SC, Ishani A, Collins AJ, Foley RN (2005) Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int 68(1):293–301
Kamei J, Kasyya Y (1992) Antitussive effects of Ca2+channel antagonists. Eur J Pharmacol 212:61–66
Kaplan NM (2015) Indapamide: is it the better diuretic for hypertension? Hypertension 65(5):983–984
Kenneth Jamerson, Michael A. Weber, George L. Bakris, Björn Dahlöf, Bertram Pitt, Victor Shi, Allen Hester, Jitendra Gupte, Marjorie Gatlin, and Eric J. Velazquez, for the ACCOMPLISH Trial Investigators. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N Engl J Med 2008; 359:2417–2428. https://doi.org/10.1056/nejmoa0806182
Kenneth L. Becker (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 708, 777, 1087, 1196. ISBN 978–0-7817-1750-2.]
Kent DM, Jafar TH, Hayward RA, Tighiouart H, Landa M, de Jong P, de Zeeuw D, Remuzzi G, Kamper AL, Levey AS (2007) Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 18:1959–1965
Kidney Disease: Improving Global Outcomes (KDIGO) (2012) Blood Pressure Work Group: KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2:337–414
Knoll GA, Sahgal A, Nair RC, Graham J, van Walraven C, Burns KD (2002) Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med 112:110–114
Kokubo Y, Kamide K (2009) High-normal blood pressure and the risk of cardiovascular disease. Circ J 73:1381–1385
Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR; SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005; 95:29–35. pmid:15619390
Kovesdy CP, Bleyer AJ, Molnar MZ, et al (2013) Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. Ann Intern Med 159(4):233–242. PubMed: 24026256
Krum H, Carson P, Farsang C, Maggioni AP, Glazer RD, Aknay N, Chiang YT, Cohn JN (2004). Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. European Journal of Heart Failure. 6 (7): 937–45. https://doi.org/10.1016/j.ejheart.2004.09.005. pmid 15556056
Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C (2015) Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Int J Cardiol 200:25–29
Lakhan SE, Sapko MT (2009) Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis. Int Arch Med. 2:30
Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Townsend RR, Xie D, Cifelli D, Cohan J, Fink JC, Fischer MJ, Gadegbeku C, Hamm LL, Kusek JW, Landis JR, Narva A, Robinson N, Teal V, Feldman HI; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol. 2009; 4(8):1302– 1311. [PubMed: 19541818]
Laurent Stéphane (2017) Antihypertensive drugs. Pharmacol Res 124:116–125
Law M, Wald N, Morris J (2003b) Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy (PDF). Health Technol Assess 7(31):1–94
Law MR, Wald NJ, Morris JK, Jordan RE (2003a) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326:1427
Law MR1, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338: b1665-b1665. https://doi.org/10.1136/bmj.b1665
Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc. 1999 Jan;47(1):40–50
Leonetti G, Rappelli A, Salvetti A, Scapellato L. Long-term effects of indapamide: final results of a two-year Italian multicenter study in systemic hypertension. Am J Cardiol 1990; 65:67H–71Hpmid:2184655
Levy BI (2005) How to explain the differences between renin angiotensin system modulators. Am J Hypertens 18(9 Pt 2):134S–141S. https://doi.org/10.1016/j.amjhyper.2005.05.005
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (London, England). 2002; 360:1903–1913
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I (2001) Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860
Lewis G. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers’ Lives: Reviewing Maternal Deaths to Make Motherhood Safer ‐ 2003–2005. The Seventh Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. London: CEMACH; 2007
Liang W, Ma H, Cao L, Yan W, Yang J (2017a) Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis. J Cell Mol Med 21(11):2634–2642. https://doi.org/10.1111/jcmm.13205
Liang W, Ma H, Cao L, Yan W, Yang J (2017) Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis J Cell Mol Med 21(11):2634–2642
Lim PO, Jung RT, MacDonald TM (1997) Screening for primary hyperaldosteronism in a hospital hypertensive population: is it the commonest form of secondary hypertension? J Hypertens 15:1531–1532
Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock C, Bucello C, Buchbinder R, Bull F, Burnett RT, Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, Chen JS, Cheng AT, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, Darling S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M, Ding EL, Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin PJ, Fahimi S, Falder G, Farzadfar F, Ferrari A, Finucane MM, Flaxman S, Fowkes FG, Freedman G, Freeman MK, Gakidou E, Ghosh S, Giovannucci E, Gmel G, Graham K, Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W, Hoek HW, Hogan A, Hosgood HD 3rd, Hoy D, Hu H, Hubbell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang YH, Khatibzadeh S, Khoo JP, Kok C, Laden F, Lalloo R, Lan Q, Lathlean T, Leasher JL, Leigh J, Li Y, Lin JK, Lipshultz SE, London S, Lozano R, Lu Y, Mak J, Malekzadeh R, Mallinger L, Marcenes W, March L, Marks R, Martin R, McGale P, McGrath J, Mehta S, Mensah GA, Merriman TR, Micha R, Michaud C, Mishra V, Mohd Hanafiah K, Mokdad AA, Morawska L, Mozaffarian D, Murphy T, Naghavi M, Neal B, Nelson PK, Nolla JM, Norman R, Olives C, Omer SB, Orchard J, Osborne R, Ostro B, Page A, Pandey KD, Parry CD, Passmore E, Patra J, Pearce N, Pelizzari PM, Petzold M, Phillips MR, Pope D, Pope CA 3rd, Powles J, Rao M, Razavi H, Rehfuess EA, Rehm JT, Ritz B, Rivara FP, Roberts T, Robinson C, Rodriguez-Portales JA, Romieu I, Room R, Rosenfeld LC, Roy A, Rushton L, Salomon JA, Sampson U, Sanchez-Riera L, Sanman E, Sapkota A, Seedat S, Shi P, Shield K, Shivakoti R, Singh GM, Sleet DA, Smith E, Smith KR, Stapelberg NJ, Steenland K, Stöckl H, Stovner LJ, Straif K, Straney L, Thurston GD, Tran JH, Van Dingenen R, van Donkelaar A, Veerman JL, Vijayakumar L, Weintraub R, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams W, Wilson N, Woolf AD, Yip P, Zielinski JM, Lopez AD, Murray CJ, Ezzati M, AlMazroa MA, Memish ZA. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224–60. https://doi.org/10.1016/s0140-6736(12)61766-8
Lin SH, Yang SS, Chau T, Halperin ML (2003) An unusual cause hypokalemic paralysis: chronic licorice ingestion. Am J Med Sci 325(3):153–156. https://doi.org/10.1097/00000441-200303000-00008 pmid 12640291
Liu L, Wang Z, Gong L, Zhang Y, Thijs L, Staessen JA, Wang J (2009) Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res 32:1032–1040. https://doi.org/10.1038/hr.2009.139
Loffing, Johannes; Kaissling, Brigitte (2003). Sodium and calcium transport pathways along the mammalian distal nephron: from rabbit to human. Am J Physiol Renal Physiol. 284 (4): F628–F643. https://doi.org/10.1152/ajprenal.00217.2002. pmid 12620920
London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME (2001) Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 12:2759–2767 [PubMed: 11729246]
Lévy BI (2004) Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin–angiotensin system. Circulation 109(1):8–13. https://doi.org/10.1161/01.cir.0000096609.73772.c5
MacCarthy EP, Bloomfield SS (1983) Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy 3(4):193–219
Madkour H, Gadallah M, Riveline B, Plante GE, Massry SG. Indapamide is superior to thiazide in the preservation of renal function in patients with renal insufficiency and systemic hypertension. Am J Cardiol. 1996; 77: 23b–5b
Magee LA, Cham C, Waterman EJ, Ohlsson A, Von Dadelszen P (2003) Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 327(7421):955–960. https://doi.org/10.1136/bmj.327.7421.955. PMCID: PMC259162. PMID: 14576246
Makani H, Messerli FH, Romero J, Wever-Pinzon O, Korniyenko A, Berrios RS, Bangalore S (2012) Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol 110:383–391. https://doi.org/10.1016/j.amjcard.2012.03.034 Epub 2012 Apr 20
Malha L, Mann SJ (2016) Loop diuretics in the treatment of hypertension. Curr Hypertens Rep 18(4):27. https://doi.org/10.1007/s11906-016-0636-7
Mancia G (2006) Total cardiovascular risk: a new treatment concept. J Hypertens Suppl 24:S17–S24
Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31(7):1281–1357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc
Marie Smith, Jason Waugh, Catherine Nelson‐Piercy. Management of postpartum hypertension. The Obstetrician & Gynaecologist. 2013; 15:45–50. First published: 11 January 2013. https://doi.org/10.1111/j.1744-4667.2012.00144.x
Martínez-Salamanca JI, La Fuente JM, Cardoso J, Fernández A, Cuevas P, Wright HM, Angulo J (2014) Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway. J Sex Med. 11(5):1182–1192
Mary C Corretti, Todd J Anderson, Emelia J Benjamin, David Celermajer, Francois Charbonneau, Mark A Creager, John Deanfield, Helmut Drexler, Marie Gerhard-Herman, David Herrington, Patrick Vallance, Joseph Vita and Robert Vogel. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery A report of the International Brachial Artery Reactivity Task Force Journal of the American College of Cardiology.Volume 39, Issue 2, January 2002DOI: https://doi.org/10.1016/s0735-1097(01)01746-6
Mathur R, Braunstein GD (1997). “Gynecomastia:pathomechanisms and treatment strategies”. Horm. Res. 48 (3): 95–102. https://doi.org/10.1159/000185497. pmid 11546925
Matthew Denker, Suzanne Boyle, Amanda H. Anderson, Lawrence J. Appel, Jing Chen, Jeffrey C. Fink, John Flack, Alan S. Go, Edward Horwitz, Chi-yuan Hsu, John W. Kusek, James P. Lash, Sankar Navaneethan, Akinlolu O. Ojo, Mahboob Rahman, Susan P. Steigerwalt, Raymond R. Townsend, and Harold I. Feldman for the Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Chronic Renal Insufficiency Cohort Study (CRIC): Overview and Summary of Selected Findings. Clin J Am Soc Nephrol 10: 2073–2083, 2015. https://doi.org/10.2215/cjn.04260415
Mazzuchi N, Carbonell E, Fernandez-Cean J (2000) Importance of blood pressure control in hemodialysis patient survival. Kidney Int 58:2147–2154 [PubMed: 11044236]
McClelland RL, Jorgensen NW, Budoff M, Blaha MJ, Post WS, Kronmal RA, Bild DE, Shea S, Liu K, Watson KE, Folsom AR, Khera A, Ayers C, Mahabadi AA, Lehmann N, Jöckel KH, Moebus S, Carr JJ, Erbel R, Burke GL.10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study). J Am Coll Cardiol. 2015 Oct 13;66(15):1643–53. https://doi.org/10.1016/j.jacc.2015.08.035
McDonough Caitrin W, Burbage Sarah E, Duarte Julio D, Gong Yan, Langaee Taimour Y, Turner Stephen T, Gums John G, Chapman Arlene B, Bailey Kent R, Beitelshees Amber L, Boerwinkle Eric, Pepine Carl J, Cooper-DeHoff Rhonda M, Johnson Julie A (2013) Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J Hypertens 31(4):698–704. https://doi.org/10.1097/hjh.0b013e32835e2a71
McInnes GT (2008) Clinical Pharmacology and Therapeutics of Hypertension. Elsevier. p. 125. ISBN 978–0-444-51757-9
Messerli FH, Bangalore S (2017) Angiotensin receptor blockers reduce cardiovascular events, including the risk of myocardial infarction. Circulation 135:2085–2087
Messerli Franz H, Bangalore Sripal, Bavishi Chirag, Rimoldi Stefano F (2018) Angiotensin-Converting Enzyme Inhibitors in Hypertension To Use or Not to Use? J Am Coll Cardiol 71:1474–1482
Messerli Franz, Makani Harikrishna, Benjo Alexandre, Romero Jorge, Alviar Carlos, Bangalore Sripal (2011) Antihypertensive Efficacy of Hydrochlorothiazide as Evaluated by Ambulatory Blood Pressure Monitoring: A Meta-Analysis of Randomized Trials. J Am Coll Cardiol 57(5):590–600. https://doi.org/10.1016/j.jacc.2010.07.053
Messerli FH, Nussberger J (2000) Vasopeptidase inhibition and angio-oedema. Lancet 356:608–609
Messerli FH, Williams B, Ritz E (2007) Essential hypertension. Lancet 370(9587):591–603
Minutolo R, Agarwal R, Borrelli S et al (2011) Prognostic role of ambulatory blood pressure measurement in patients with non-dialysis chronic kidney disease. Arch Intern Med 171(12):1090–1098 [PubMed: 21709109]
Miriam Russ, Susanne Jauk, Reinhold Wintersteiger, Bernd Gesslbauer, Joachim Grelberger, Michaela Andra, Astrid Ortner. Stabilization of Angiotensin-(1–7) in Cardioprotective Solutions. Int J Pept Res Ther (2018). https://doi.org/10.1007/s10989-018-9773-y
Mohan IV, Bourke V (2015) The management of renal artery stenosis: an alternative interpretation of ASTRAL and CORAL. RAS Eur J Vasc Endovasc Surg. 49(4):465–473. https://doi.org/10.1016/j.ejvs.2014.12.026 Epub 2015 Feb 26
Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, Hulbert-Shearon T, Jones CA, Bloembergen WE (2000) Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 11:556–564 [PubMed: 10703680]
Mojon A, Ayala DE, Pineiro L et al (2013) Comparison of ambulatory blood pressure parameters of hypertensive patients with and without chronic kidney disease. Chronobiol Int 30(1–2):145–158 [PubMed: 23181690]
Moore JX, Chaudhary N, Akinyemiju T (2017) Metabolic Syndrome Prevalence by Race/Ethnicity and Sex in the United States, National Health and Nutrition Examination Survey, 1988-2012. Prev Chronic Dis. 16(14):E24. https://doi.org/10.5888/pcd14.160287
Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B (2014) Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest 145(4):779–786. https://doi.org/10.1378/chest.13-1235
Morgenstern LB, Hemphill JC 3rd, Anderson C, Becker K, Broderick JP, Connolly ES Jr, Greenberg SM, Huang JN, MacDonald RL, Messé SR, Mitchell PH, Selim M, Tamargo RJ; American Heart Association Stroke Council and Council on Cardiovascular Nursing. on behalf of the American Heart Association Stroke Council and Council on Cardiovascular Nursing. (2010). Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 41(9), 2108–2129. https://doi.org/10.1161/str.0b013e3181ec611b
Mostalac-Preciado CR, de Gortari P, López-Rubalcava C (September 2011). Antidepressant-like effects of mineralocorticoid but not glucocorticoid antagonists in the lateral septum: interactions with the serotonergic system. Behav. Brain Res. 223 (1): 88–98. https://doi.org/10.1016/j.bbr.2011.04.008. pmid 21515309
Mousa AY, Bates MC, Broce M, Bozzay J, Morcos R, AbuRahma AF (2017a) Issues related to renal artery angioplasty and stenting. Vascular. 25(6):618–628. https://doi.org/10.1177/1708538116677654 Epub 2017 Aug 7
Mousa AY, Bates MC, Broce M, Bozzay J, Morcos R, AbuRahma AF (2017) Issues related to renal artery angioplasty and stenting. Vascular 25(6):618–628. https://doi.org/10.1177/1708538116677654. Epub 2017 Aug 7. Campese V, Adenuga G. Renovascular disease: Is there still a role for revascularization. Clin Nephrol 89(4):229–240. https://doi.org/10.5414/cn109239
Multiple risk factor intervention trial (1982) Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA. 1982 Sep 24;248(12):1465–77
Multiple Risk Factor Intervention Trial Group. “The Multiple Risk Factor Intervention Trial (MRFIT). A national study of primary prevention of coronary heart disease. (1976) JAMA, 1976, 235(8): 825–827
Muntner P, Whittle J, Lynch AI, Colantonio LD, Simpson LM, Einhorn PT, Levitan EB, Whelton PK, Cushman WC, Louis GT, Davis BR, Oparil S (2015) Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med 163(5):329–338. https://doi.org/10.7326/m14-2803
Muntner P, Gutiérrez OM, Zhao H, Fox CS4, Wright NC, Curtis JR5, McClellan W, Wang H, Kilgore M, Warnock DG, Bowling CB.Validation study of medicare claims to identify older US adults with CKD using the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Kidney Dis. 2015 Feb;65(2):249–58. https://doi.org/10.1053/j.ajkd.2014.07.012. Epub 2014 Sep 19
Muntner P, Whittle J, Lynch AI, Colantonio LD, Simpson LM, Einhorn PT, Levitan EB, Whelton PK, Cushman WC, Louis GT, Davis BR, Oparil S. Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med. 2015 Sep 1;163(5):329–38. https://doi.org/10.7326/m14-2803
Murray CJ, Abraham J, Ali MK, Alvarado M, Atkinson C, Baddour LM, Bartels DH, Benjamin EJ, Bhalla K, Birbeck G, Bolliger I, Burstein R, Carnahan E, Chen H, Chou D, Chugh SS, Cohen A, Colson K, Cooper LT, Couser W, Criqui MH, Dabhadkar KC, Dahodwala N, Danaei G, Dellavalle RP, Jarlais DC, Dicker D, Ding EL, Dorsey E, Duber H, Ebel BE, Engell RE, Ezzati M, Felson DT, Finucane MM, Flaxman S, Flaxman AD, Fleming T, Forouzanfar MH, Freedman G, Freeman MK, Gabriel SE, Gakidou E, Gillum RF, Gonzalez-Medina D, Gosselin R, Grant B, Gutierrez HR, Hagan H, Havmoeller R, Hoffman H, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Kassebaum N, Khatibzadeh S, Knowlton LM, Lan Q, Leasher JL, Lim S, Lin JK, Lipshultz SE, London S, Lozano R, Lu Y, MacIntyre MF, Mallinger L, McDermott MM, Meltzer M, Mensah GA, Michaud C, Miller TR, Mock C, Moffitt TE, Mokdad AA, Mokdad AH, Moran AE, Mozaffarian D, Murphy T, Naghavi M, Narayan K, Nelson RG, Olives C, Omer SB, Ortblad K, Ostro B, Pelizzari PM, Phillips D, Pope C 3rd, Raju M, Ranganathan D, Razavi H, Ritz B, Rivara FP, Roberts T, Sacco RL, Salomon JA, Sampson U, Sanman E, Sapkota A, Schwebel DC, Shahraz S, Shibuya K, Shivakoti R, Silberberg D, Singh GM, Singh D, Singh JA, Sleet DA, Steenland K, Tavakkoli M, Taylor JA, Thurston GD, Towbin JA, Vavilala MS, Vos T, Wagner GR, Weinstock MA, Weisskopf MG, Wilkinson JD, Wulf S, Zabetian A, Lopez AD (2013) The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA 310:591–608. https://doi.org/10.1001/jama.2013.13805
Musini VM, Rezapour P, Wright JM, Bassett K, Jauca CD, Blood pressure-lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev 2015; 5: CD003825
Ménard J (2004) The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol 217(1–2):45–52. https://doi.org/10.1016/j.mce.2003.10.008 pmid 15134800
NICE guideline [NG133]: Hypertension in pregnancy: diagnosis and management. Published date: June 2019
National Institute for Health and Clinical Excellence (NICE) 2006, Hypertension: management of hypertension in adults in primary care. NICE clinical guideline 34 (Partial update of NICE clinical guideline 18). www.nice.org.uk N1050 70 k 1p Jun 06, ISBN 1–84629-222-0
National Institute for Health and Clinical Excellence. Hypertension in Pregnancy. The Management of Hypertensive Disorders in Pregnancy. London: NICE; 2010
National Institute for Health and Clinical Excellence. Routine Postnatal Care of Women and their Babies. London: NICE; 2006
National Kidney Foundation. K/DOQI Clinical Practice Guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005; 45 Suppl. 4: S49–S59. S69–S75
National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis, 39 (Suppl 1) (2002), pp. S1-S266
National Kidney and Urologic Diseases Information Clearinghouse. Kidney and urology diseases statistic for the United States. http://kidney.niddk.nih.gov/kudiseases/pubs/kustats/. Accessed 14 Jan 2010]
Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, Wentworth D. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 1490–1500
Nebivolol Pregnancy and Breastfeeding Warnings”. Drugs.com. Retrieved 3 March 2019
Nebivolol side effects site:www.drugs.com. Medically reviewed by Drugs.com. Last updated on Jun 12, 2019
Nebivolol Hydrochloride Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019
Nelson M (2010) Drug treatment of elevated blood pressure (PDF). Australian Prescriber 33(4):108–112. https://doi.org/10.18773/austprescr.2010.055
Nelson, M.Drug treatment of elevated blood pressure, Australian Prescriber, 33, (4) pp. 108–112. ISSN 0312-8008 (2010) [Professional]
Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P Tremblay G, McLean D, Padwal RS, Tran KC, Grover S, Rabkin SW, Moe GW, Howlett JG, Lindsay P, Hill MD, Sharma M, Field T, Wein TH, Shoamanesh A, Dresser GK, Hamet P, Herman RJ, Burgess E, Gryn SE, Grégoire JC, Lewanczuk R, Poirier L, Campbell TS, Feldman RD, Lavoie KL, Tsuyuki RT, Honos G, Prebtani APH, Kline G, Schiffrin EL, Don-Wauchope A, Tobe SW, Gilbert RE, Leiter LA, Jones C, Woo V, Hegele RA, Selby P, Pipe A, McFarlane PA, Oh P7, Gupta M, Bacon SL, Kaczorowski J, Trudeau L, Campbell NRC, Hiremath S, Roerecke M, Arcand J, Ruzicka M, Prasad GVR, Vallée M, Edwards C, Sivapalan P, Penner SB, Fournier A, Benoit G, Feber J, Dionne J, Magee LA, Logan AG, Côté AM, Rey E, Firoz T, Kuyper LM, Gabor JY, Townsend RR, Rabi DM, Daskalopoulou SS. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Can J Cardiol. 2018 May;34(5):506–525. (Canada guideline 2018) https://doi.org/10.1016/j.cjca.2018.02.022
Neymark E, LaBerge JM, Hirose R, Melzer JS, Kerlan RK Jr, Wilson MW, Gordon RL (2000) Arteriographic detection of renovascular disease in potential renal donors: incidence and effect on donor surgery. Radiology 214:755–760
Nuttall SL, Routledge HC, Kendall MJ (June 2003). A comparison of the beta1-selectivity of three beta1-selective beta-blockers”. J Clin Pharm Ther. 28 (3): 179–86. https://doi.org/10.1046/j.1365-2710.2003.00477.x. pmid 12795776
Olde Engberink RH, Frenkel WJ, van den Bogaard B, Brewster LM, Vogt L, van den Born BJ (2015) Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension 65(5):1033–1040
Omar HR, Komarova I, El-Ghonemi M, Fathy A, Rashad R, Abdelmalak HD, Yerramadha MR, Ali Y, Helal E, Camporesi EM (2012) Licorice abuse: time to send a warning message. Ther Adv Endocrinol Metab. 3(4):125–138. https://doi.org/10.1177/2042018812454322 pmc 3498851. pmid 23185686
Otte C, Hinkelmann K, Moritz S et al (2010) Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof pf-concept study. J Psychiatr Res 44(6):339–346. https://doi.org/10.1016/j.jpsychires.2009.10.006 pmid 19909979
O’Riordan, Michael. ”PATHWAY3: Amiloride-HCTZ Lowers BP With Neutral Effect on Glucose, Potassium”. www.medscape.com. WebMD LLC. Retrieved 9 June 2018
PROGRESS Collaborative Group (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet 358(9287):1033–1041
Parthasarathy HK, MacDonald TM (2007) Mineralocorticoid receptor antagonists. Curr Hypertens Rep 9(1):45–52. https://doi.org/10.1007/s11906-007-0009-3 pmid 17362671
Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358:2433–2446. https://doi.org/10.1056/nejmoa0708379
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; (2012) Altitude investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367(23):2204–2213. https://doi.org/10.1056/nejmoa1208799. Epub 2012 Nov 3
Paton RR, Kane RE (1977) Long-term diuretic therapy with metolazone of renal failure and the nephrotic syndrome. J Clin Pharmacol 17(4):243–251
Patrick A. McKee. William P. Castelli, Patricia M. McNamara, and William B. Kannel. The Natural History of Congestive Heart Failure: The Framingham Study. N Engl J Med 1971; 285:1441–1446. https://doi.org/10.1056/nejm197112232852601
Paul Muntner, Barry R. Davis, William C. Cushman, Sripal Bangalore, David A. Calhoun, Sara L. Pressel, Henry R. Black, John B. Kostis, Jeffrey L. Probstfield, Paul K. Whelton, and Mahboob Rahman and for the ALLHAT Collaborative Research Group*Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014; 64:1012–1021
Pelliccia F, Patti G, Rosano G, Greco C, Gaudio C (2014) Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis. Int J Cardiol 177:219–228
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) (2012) Eur Heart J 33(17):1635–2170
Pessina AC (December 2001). Metabolic effects and safety profile of Nebivolol J. Cardiovasc. Pharmacol. 38. Suppl 3: S33–5. PMID 11811391
Pettinger (1980) Minoxidil and the treatment of severe hypertension. N Engl J Med 303:922–926. https://doi.org/10.1056/nejm198010163031607
Pisoni R, Acelajado MC, Cartmill FR et al (2012) Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens 26(8):502–506 [PubMed: 21677673]
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383–1392
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) Randomized Aldactone Evaluation Study Investigators: the effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709–717
Plouin PF (2003) Stable patients with atherosclerotic renal artery stenosis should be treated first with medical managemen. Am J Kidney Dis 42:851–857
Pogue V, Rahman M, Lipkowitz M, Toto R, Miller E, Faulkner M, Rostand S, Hiremath L, Sika M, Kendrick C, Hu B, Greene T, Appel L, Phillips RA, African American Study of Kidney Disease and Hypertension Collaborative Research Group. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension. 2009; 53(1):20–27. [PubMed: 19047584]
Poirier L, Cléroux J, Nadeau A, Lacourcière Y (2001) Effects of Nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 19(8):1429–1435. https://doi.org/10.1097/00004872-200108000-00011 pmid 11518851
Prescribing information for Bystolic (PDF). Retrieved 2009–06-11
Price, RS; Kasner, SE (2014). Hypertension and hypertensive encephalopathy Handbook of clinical neurology. 2014,119: 161–7
Prince M, Tafur JD, White CJ (2019) When and How Should We Revascularize Patients With Atherosclerotic Renal Artery Stenosis? JACC Cardiovasc Interv. 12(6):505–517. https://doi.org/10.1016/j.jcin.2018.10.023
Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS (2003) Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289:2534–2544. pmid:12759325
Punit S. Ramrakha; Punit Ramrakha; Jonathan Hill (23 February 2012). Oxford Handbook of Cardiology. OUP Oxford. pp. 107–. ISBN 978–0-19-964321-9
Qadri, Yawar J.; Rooj, Arun K.; Fuller, Catherine M. (April 2012). ENaCs and ASICs as therapeutic targets. American Journal of Physiology. Cell Physiology. 302 (7): C943–C965. https://doi.org/10.1152/ajpcell.00019.2012
Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, Moy CS, Silbergleit R, Steiner T, Suarez JI, Toyoda K, Wang Y, Yamamoto H, Yoon BW; ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network. Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. N Engl J Med 2016; 375:1033–1043. https://doi.org/10.1056/nejmoa1603460
Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, Gibbs JS, Gohlke-Baerwolf C, Gorenek B, Iung B, Kirby M. European Society of Gynecology (ESG); Association for European Paediatric Cardiology (AEPC); German Society for Gender Medicine (DGesGM); ESC Committee for Practice Guidelines. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the task force on the Management of cardiovascular diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2;32(24):3147–3197. https://doi.org/10.1093/eurheartj/ehr21
Remonti LR, Dias S, Leitao CB, Kramer CK, Klassman LP, Welton NJ, Ades AE, Gross JL (2016) Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetes-network meta-analysis of randomized trials. J Diabetes Complications 30:1192–1200. https://doi.org/10.1016/j.jdiacomp.2016.04.020
Reudelhuber TL (2005) The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous. Hypertension 46(6):1261–1262. https://doi.org/10.1161/01.hyp.0000193498.07087.83
Ripley TL, Saseen JJ (2014) β-blockers: a review of their pharmacological and physiological diversity in hypertension. Ann Pharmacother 48(6):723–733. https://doi.org/10.1177/1060028013519591 Epub 2014 Mar 31
Ripley TL1, Saseen JJ. β-blockers: a review of their pharmacological and physiological diversity in hypertension. Ann Pharmacother. 2014 Jun;48(6):723–33. https://doi.org/10.1177/1060028013519591. Epub 2014 Mar 31
Robert M. Carey, David A. Calhoun, George L. Bakris, Robert D. Brook, Stacie L. Daugherty, Cheryl R. Dennison-Himmelfarb, Brent M. Egan, John M. Flack, Samuel S. Gidding, Eric Judd, Daniel T. Lackland, Cheryl L. Laffer, Christopher Newton-Cheh, Steven M. Smith, Sandra J. Taler, Stephen C. Textor, Tanya N. Turan, William B. White, and on behalf of the American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018;72: e53–e90
Rocha-Singh KJ, Eisenhauer AC, Textor SC, Cooper CJ, Tan WA, Matsumoto AH, Rosenfield K (2008) American Heart Association Writing Group 8. Atherosclerotic Peripheral Vascular Disease Symposium II: intervention for renal artery disease. Circulation 118(25):2873–2878. https://doi.org/10.1161/circulationaha.108.191178
Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S1, Maclagan K, Nicolaides KH. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017 Aug 17;377(7):613–622. https://doi.org/10.1056/nejmoa1704559
Rosemary Townsend, Patrick O’Brien, Asma Khalil. Current best practice in the management of hypertensive disorders in pregnancy. Integrated Blood Pressure Control 2016:9 79–94
Rosenberg J, Gustafsson F, Galatius S, Hildebrandt PR (2005) Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. Cardiovasc Drugs Ther 19(4):301–306
Rossier Bernard C, Schild Laurent (2008) Epithelial Sodium Channel, Mendelian Versus Essential Hypertension. Hypertension 52:595–600. https://doi.org/10.1161/HYPERTENSIONAHA.107.097147
Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA (2015a) Head-to-head comparisons of hydrochlorothiazide with Indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension 65:1041–1046. https://doi.org/10.1161/hypertensionaha.114.05021
Roush GC, Ernst ME, Kostis JB, Kaur R, Sica DA (2015b) Not just chlorthalidone: evidence-based, single tablet, diuretic alternatives to hydrochlorothiazide for hypertension. Curr Hypertens Rep 17(4):540
Roush GC, Kaur R, Ernst ME (2014) Diuretics: a review and update. J. Cardiovasc. Pharmacol. Ther. 19(1):5–13. https://doi.org/10.1177/1074248413497257 pmid 24243991
Rupesh Raina, Vinod Krishnappa, Taryn Blaha,Taylor Kann, William Hein,Linda Burke, and Arvind Bagga. Review Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Therapeutic Apheresis and Dialysis 2019; 23(1):4–21. https://doi.org/10.1111/1744-9987.12763 © 2018
SHEP Study: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEPCooperative Research Group. JAMA 265(24):3255–3264
SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116. https://doi.org/10.1056/nejmoa1511939
Sacks FM, Campos H (2010) Dietary therapy in hypertension. N Engl J Med 362:2102–2112
Safian RD, Textor SC (2001) Renal artery stenosis. N Engl J Med 344:431–442
Saiz LC, Gorricho J, Garjón J, et al (2018) Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev (7):CD010315
Salassa RM, Mattox VR, Rosevear JW (1962) “Inhibition of the mineralocorticoid” activity of licorice by spironolactonbe. J Clin Endocrinol Metab 22(11):1156–1159. https://doi.org/10.1210/jcem-22-11-1156 pmid 13991036
Samadian F, Dalili N, Jamalian A (2017) New insights into pathophysiology, diagnosis, and treatment of renovascular hypertension. Iran J Kidney Dis. 11(2):79–89
Saydah S, Bullard KM, Cheng Y, et al (2014) Trends in cardiovascular disease risk factors by obesity level in adults in the United States, NHANES 1999–2010. Obesity (Silver Spring). 2014; 22:1888–95
Scantlebury DC, Hayes SN (2014) How does pre-eclampsia predispose to future cardiovascular disease? Curr Hypertens Rep 16(9):472
Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommelé Å, Kupelian V, Gasteyger C, Greenbaum LA, Johnson S (2018) Global aHUS Registry. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int 94(2):408–418. https://doi.org/10.1016/j.kint.2018.02.029
Scheen AJ (2018) Type 2 diabetes and thiazide diuretics. Curr Diab Rep 18:6. https://doi.org/10.1007/s11892-018-0976-6
Schirpenbach C, Reincke M (2007) Primary aldosteronism, current knowledge and controversies in Conn’s syndrome. Nat Clin Practice Endocrinol Metab 3(3):220–227
Seng DS, Kwong J, Rezvani F, Coates AO (2009) Angiotensin-converting enzyme-related cough among Chinese-Americans. Am J Med 123(2):183. e11–e15. https://doi.org/10.1016/j.amjmed.2009.06.032
Sevillano ÁM, Cabrera J, Gutiérrez E, Morales E, Mérida E, Huerta A, Cavero T, Hernández E, Moreno JA, Praga M. Malignant hypertension: a type of IgA nephropathy manifestation with poor prognosis. Nefrologia 35(1):42–9. https://doi.org/10.3265/nefrologia. pre 2014.Oct.12735
Shah S, Khatri I, Freis ED (1978) Mechanism of antihypertensive effect of thiazide diuretics. Am Heart J 95:611–618
Shamiss A, Carroll J, Peleg E, Grossman E, Rosenthal T (1995) The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. Am J Hypertens 8:276–281. PMID 7794577
Shamon SD, Perez MI (2009) Blood pressure lowering efficacy of reserpine for primary hypertension. Cochrane Database Syst Rev. (4):CD007655. https://doi.org/10.1002/14651858.cd007655.pub2
Sharabi Y, Adler E, Shamis A, Nussinovitch N, Markovitz A, Grossman E (2006) Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 19:750–755. PMID 16814132
Sharma C, Soni A, Gupta A, Verma A, Verma S (2017) Hydralazine vs nifedipine for acute hypertensive emergency in pregnancy: a randomized controlled trial. Am J Obstet Gynecol 217(6):687.e1–687.e6. https://doi.org/10.1016/j.ajog.2017.08.018
Shenasa Mohammad, Shenasa Hossein (2017) Hypertension, left ventricular hypertrophy, and sudden cardiac death. Int J Cardiol 237:60–63
Sica Domenic A (2003) The African American Study of Kidney Disease and Hypertension (AASK) Trial: What More Have We Learned? J Clin Hypertens. 5:159–167
Sica DA, Gehr TW (1989) Triamterene and the kidney. Nephron 51(4):454–461
Sica DA, Grubbs R. Transdermal clonidine: therapeutic considerations. J Clin Hypertens (Greenwich) 7(9):558–562
Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions. Elsevier Science. 1 December 2014. p. 293. ISBN 978-0-444-63391-0
Sidorenkov G, Navis G (2014) Safety of ACE inhibitor therapies in patients with chronic kidney disease. Expert Opinion Drug Safety 13(10):1383–1395. https://doi.org/10.1517/14740338.2014.951328 pmid 25148900
Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WH, Ewan PW (1988) Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 260:967–970
Smith A, Gaba RC, Bui JT, Minocha J. Management of Renovascular Hypertension. Tech Vasc Interv Radiol 19(3):211–217. https://doi.org/10.1053/j.tvir.2016.06.006. Epub 2016 Jun 3
Smyth A, O’Donnell MJ, Yusuf S et al (2014) Sodium intake and renal outcomes: a systematic review. Am J Hypertens 27(10):1277–1284 [PubMed: 24510182]
Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA (2005) Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 111(25):3411–3419. https://doi.org/10.1161/circulationaha.104.508093. PMID 15967846
Stamler J, Neaton ND, Cohen JD, Cutler J, Eberly L, Grandits G, Kuller LH, Ockene J, Prineas R (2012) Research Group. Multiple risk factor intervention trial revisited: a new perspective based on nonfatal and fatal composite endpoints, coronary and cardiovascular, during the trial. J Am Heart Assoc 1(5):e003640. https://doi.org/10.1161/jaha.112.003640
Stirnadel-Farrant HA, Karaboyas A, Cizman B, Bieber BA, Kler L, Jones D, Cobitz AR, Robinson BM (2019) Cardiovascular Event Rates Among Hemodialysis Patients Across Geographical Regions-A Snapshot From The Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int Rep 4(6):864–872. https://doi.org/10.1016/j.ekir.2019.03.016. eCollection 2019 Jun
Struthers Allan, Krum Henry, Williams Gordon H (2008) A Comparison of the aldosterone-blocking Agents eplerenone and spironolactone. Clin Cardiol 31(4):153–158
Sturkenboom MCJM, Dieleman JP, Picelli G, Mazzaglia G, Mozaffari E, Filippi A, Cricelli C, van der Lei J (2008) Prevalence and treatment of hypertensive patients with multiple concomitant cardiovascular risk factors in The Netherlands and Italy. J Hum Hypertens 22:704–713
Sullivan TJ (1991) Cross-reactions among furosemide, hydrochlorothiazide, and sulfonamides. JAMA 265(1):120–121
Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R (2008) Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 52:501–506 [PubMed: 18653268]
Tajeu GS, Booth III JN, Colantonio LD, Gottesman RF, Howard G, Lackland DT, O’Brien EC, Oparil S, Ravenell J, Safford MM, Seals SR (2017) Incident cardiovascular disease among adults with blood pressure. Circulation. 136:798–812. https://doi.org/10.1161/circulationaha.117.027362
Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, Dohi Y (2006) Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis—a randomized study. Nephrol Dial Transplant 21:2507–2512 [PubMed: 16766543]
Takeda A, Toda T, Fujii T, Shinohara S, Sasaki S, Matsui N (2005) Discordance of influence of hypertension on mortality and cardiovascular risk in hemodialysis patients. Am J Kidney Dis 45:112–118 [PubMed: 15696450]
Taler SJ, Textor SC, Canzanello VJ, Schwartz L (1999) Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf 20(5):437–449
Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother. 2014 Mar;15(4):527–47. https://doi.org/10.1517/14656566.2014.879118
Tamm AS, McCourt R, Gould B, Kate M, Kosior JC,Jeerakathil T, Gioia LC, Dowlatshahi D, Hill MD, Coutts SB; Demchuk AM, Buck BH, Emery DJ, Shuaib A, Butcher KS. Cerebral Perfusion Pressure is Maintained in Acute Intracerebral Hemorrhage: A CT Perfusion Study. AJNR Am J Neuroradiol. 2016; 37(2):244–51 (ISSN: 1936-959X)
Taylor AL, Ziesche S, Yancy C, Carson P, DAgostino R, Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004; 351:2049–2057
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant Subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, et al. Effects of the angiotensin-receptor blocker j telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008; 372:1174–83
Tetti M, Monticone S, Burrello J, Matarazzo P, Veglio F, Pasini B, Jeunemaitre X, Mulatero P.Liddle Syndrome: Review of the Literature and Description of a New Case. Int J Mol Sci 19(3). pii: E812. https://doi.org/10.3390/ijms19030812. Review
Tetti M, Monticone S, Burrello J, Matarazzo P, Veglio F, Pasini B, Jeunemaitre X, Mulatero P (2018) Liddle syndrome: review of the literature and description of a new case. Int J Mol Sci 19(3). https://doi.org/10.3390/ijms19030812. PMID 29534496
Thomas F, Bean K, Guize L, Quentzel S, Argyriadis P, Benetos A (2002) Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (55 years) men and women. Eur Heart J 23:528–535
Thomas MC (2000) Diuretics, ACE inhibitors and NSAIDs—the triple whammy. Med J Australia. 172(4):184–195. PMID 10772593
Thomopoulos C, Parati G, Zanchetti A (2017) Effects of blood-pressure lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 35:922–944
Thompson DF, Carter JR (1993). Drug-induced gynecomastia. Pharmacotherapy. 13(1): 37–45. https://doi.org/10.1002/j.1875-9114.1993.tb02688.x (inactive 2019-03-14). PMID 8094898
Tiotiu A, Novakova P, Kowal K, Emelyanov A, Chong-Neto H8, Novakova S, Labor M. Beta-blockers in asthma: myth and reality. Expert Rev Respir Med. 2019 Aug 2:1–8. https://doi.org/10.1080/17476348.2019.1649147
Tong S, Mol BW, Walker SP (2017) Preventing preeclampsia with aspirin: does dose or timing matter? Am J Obstet Gynecol 216(2):95–97. https://doi.org/10.1016/j.ajog.2016.12.003 PMID:28148451
Toschke AM, Gulliford MC, Wolfe CDA, Rudd AG, Heuschmann PU (2011) Antihypertensive treatment after first stroke in primary care: results from the General Practitioner Research Database. J Hypertens 29:154–160
Umesawa M, Kobashi G (2017) Epidemiology of hypertensive disorders in pregnancy: prevalence, risk factors, predictors and prognosis. Hypertens Res 40(3):213–220
Veerbeek JHW, Hermes W, Breimer AY, van Rijn BB, Koenen SV, Mol BW, Franx A, de Groot CJ, Koster MP (2015) Cardiovascular disease risk factors after early-onset preeclampsia, late-onset preeclampsia, and pregnancy-induced hypertension. Hypertension. 65:600–606. https://doi.org/10.1161/hypertensionaha.114.04850. Epub 2015 Jan 5
Velázquez H, Perazella MA, Wright FS, Ellison DH (1993) Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 119(4):296–301
Verdecchia P, Angeli F, Gentile G, Reboldi G (2016) More versus less intensive blood pressure–lowering strategy: cumulative evidence and trial sequential analysis. Hypertension 68:642–653. https://doi.org/10.1161/hypertensionaha.116.07608
Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G (2008) Effects of dietary sodium and hydrochlorothiazide on the anti-proteinuric efficacy of losartan. J Am Soc Nephrol 19(5):999–1007 [PubMed: 18272844]
WHO Model Formulary 2008 (PDF). World Health Organization. 2009. pp. 328, 330. ISBN 9789241547659. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016
Wargo K, Banta WM (2009) A comprehensive review of the loop diuretics: should furosemide be first line? Ann Pharmacother 43(11):1836–1847. https://doi.org/10.1345/aph.1m177. Epub 2009 Oct 20
Warwick J, Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N, Bulpitt C, Peters R (2017) No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the hypertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med 13:78. https://doi.org/10.1186/s12916-015-0328-1
Weber MA (2005) The role of the new beta-blockers in treating cardiovascular disease. Am J Hypertens 18(12 Pt 2):169S–176S. https://doi.org/10.1016/j.amjhyper.2005.09.009. pmid 16373195
Weiss R (2006) Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. Vasc Health Risk Manag. 2(3):303–308.https://doi.org/10.2147/vhrm.2006.2.3.303. pmc 1993984. pmid 17326335
Weiss R (2006) Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. Vasc Health Risk Manag. 2(3): 303–308. https://doi.org/10.2147/vhrm.2006.2.3.303. pmc 1993984. pmid 17326335
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines 2017 ACC/AHA/AAPA/ABC/ACPM/ AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults, A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol 2018;71:e127–248
Wile D (2012) Diuretics: a review. Ann Clin Biochem 49(Pt 5):419–431
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, De Simone G, Dominiczak A, Kahan T (2018) ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management ofarterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertension 36:1953–2041
Winkleby MA, Feldman HA, Murray DM (1997) Joint Analysis of Three U.S. Community Intervention Trials for Reduction of Cardiovascular Disease Risk. J Clin Epidemiol 50:645–658
Winter KH, Tuttle LA, Viera AJ (2013) Hypertension. Prim Care 40(1):179–194. https://doi.org/10.1016/j.pop.2012.11.008
Wiysonge CS, Opie LH (2013) β-Blockers as initial therapy for hypertension. JAMA 310(17):1851–1852. https://doi.org/10.1001/jama.2013.277510
Wong GW, Boyda HN, Wright JM (2016) Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension. Cochrane Database Syst Rev 3:CD007451. https://doi.org/10.1002/14651858.cd007451.pub2
Wood S (2014) EMA: Don’t combine ARBs, ACE inhibitors, and direct renin inhibitors. www.medscape.com
World Health Organization (2008) Global Health Observatory Data Repository. Geneva, World Health Organization. http://apps.who.int/gho/data/view.main Accessed 11 Feb 2013
Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG (2002b) African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288:2421–2431
Wright, JM, Musini VM (2009) First-line drugs for hypertension. Cochrane Database Syst Rev (3):CD001841. https://doi.org/10.1002/14651858.cd001841.pub2
Wright, Jr, Jackson T (2002a) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 288(19):2421–2431. https://doi.org/10.1001/jama.288.19.2421. ISSN 0098-7484. PMID 12435255
Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT; SPRINT Research Group (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116. https://doi.org/10.1056/nejmoa1511939
Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, Wu KD, Tu YK, Chien KL (2013) Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis. BMJ. 347: f6008. PMC 3807847. PMID 24157497. https://doi.org/10.1136/bmj.f6008
Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, Zhao N, Liu L, Lv J, Zhang H, Wang H (2016) Renin angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 67:728–41. https://doi.org/10.1053/j.ajkd.2015.10.011. Epub 2015 Nov 18
Xu R, Sun S, Huo Y, Yun L, Huang S, Li G, Yan S (2015) Effects of ACEIs versus ARBs on proteinuria or albuminuria in primary hypertension: a meta-analysis of randomized trials. Medicine (Baltimore) 94:e1560
Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A, Koizumi S (2005) Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. Clinical Nephrol 64 (1):35–40. https://doi.org/10.5414/cnp64035. Pmid 16047643
Yano Y, Rakugi H, Bakris GL, Lloyd-Jones DM, Oparil S, Saruta T, Shimada K, Matsuoka H, Imai Y, Ogihara T (2017) On-treatment blood pressure and cardiovascular outcomes in older adults with isolated systolic hypertension. Hypertension 69(2):220–227. https://doi.org/10.1161/hypertensionaha.116.08600. Epub 2017 Jan 3
Yolanda M. Hardy, Antoine T. Jenkins. Hypertensive Crises: Urgencies and Emergencies. PUBLISHED MARCH 18, 2011, US Pharm. 2011;36(3): Epub
Zhang X, Zhao Q (2016) Association of Thiazide-type diuretics with glycemic changes in hypertensive patients: a systematic review and meta-analysis of randomized controlled clinical trials. J Clin Hypertens (Greenwich) 18:342–351
Ziaeian B, Fonarow GC (2017) Maximizing cardiovascular event reduction by expanding and intensifying the targets. Circulation 136(9):813–816. https://doi.org/10.1161/circulationaha.117.029844
Zullo AR, Hersey M, Lee Y, Sharmin S, Bosco E, Daiello LA, Shah NR, Mor V, Boscardin WJ, Berard-Collins CM, Dore DD, Steinman MA (2018) Outcomes of “diabetes-friendly” vs “diabetes-unfriendly” β-blockers in older nursing home residents with diabetes after acute myocardial infarction. Diabetes Obes Metab 20(12):2724–2732. https://doi.org/10.1111/dom.13451
van den Born BH, Lip GYH, Brguljan-Hitij J, Cremer A, Segura J, Morales E, Mahfoud F, Amraoui F, Persu A, Kahan T, Agabiti Rosei E, de Simone G, Gosse P, Williams B. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):37–46. https://doi.org/10.1093/ehjcvp/pvy032. Review. Erratum in: Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):46
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Hui, R. (2020). Hypertension Drug Therapy. In: Wang, M. (eds) Coronary Artery Disease: Therapeutics and Drug Discovery. Advances in Experimental Medicine and Biology, vol 1177. Springer, Singapore. https://doi.org/10.1007/978-981-15-2517-9_6
Download citation
DOI: https://doi.org/10.1007/978-981-15-2517-9_6
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-2516-2
Online ISBN: 978-981-15-2517-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)